(Q39617773)

13 September 2017

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study (English)

1 reference

non-alcoholic steatohepatitis

13 September 2017

0 references

1 reference

1 reference

5

Koji Arihiro

1 reference

13 September 2017

8

Kazuaki Chayama

1 reference

13 September 2017

6

Hiroshi Aikata

1 reference

13 September 2017

7

Shoichi Takahashi

1 reference

13 September 2017

2

Hideyuki Hyogo

1 reference

13 September 2017

1

Takashi Nakahara

1 reference

13 September 2017

Yuki Kimura

3

1 reference

PubMed ID

22583925

13 September 2017

Tomokazu Ishitobi

series ordinal

4

1 reference

13 September 2017

14 May 2012

1 reference

13 September 2017

1 reference

13 September 2017

42

1 reference

13 September 2017

11

1 reference

13 September 2017

1065-1072

1 reference

Long term prognosis of fatty liver: risk of chronic liver disease and death.

13 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Nonalcoholic fatty liver disease and the coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Prevalence, gender, ethnic variations, and prognosis of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Review article: Drug therapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01034.X

10.1111/J.1872-034X.2012.01034.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

22583925